OS Therapies (OSTX) Enterprise Value (2023 - 2026)
OS Therapies' (OSTX) quarterly Enterprise Value came in at -$917552.0 in Q1 2026, up 69.12% YoY from -$542556.3 in Q1 2025, and down 240.05% on a QoQ basis from -$269830.0 in Q4 2025.
OS Therapies (OSTX) Enterprise Value (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Enterprise Value data on file, last reported at -$917552.0 in Q1 2026.
- Quarterly Enterprise Value rose 69.12% year-over-year to -$917552.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$917552.0 (up 69.12% YoY) and the FY2025 annual result came in at -$269830.0, up 95.12% from the prior year.
- Enterprise Value slipped to -$917552.0 in Q1 2026, from -$269830.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$16059.0 in Q3 2023 to a low of -$5.5 million in Q4 2024.
- A 4-year average of -$1.3 million and a median of -$355214.0 in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 14095.08% — and 2025, when it surged 95.12%.
- Tracing OSTX's Enterprise Value over 4 years: stood at -$38982.0 in 2023, then plunged by 14095.08% to -$5.5 million in 2024, then surged by 95.12% to -$269830.0 in 2025, then sank by 240.05% to -$917552.0 in 2026.
- The last three Enterprise Value figures came in at -$917552.0 (Q1 2026), -$269830.0 (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | OS Therapies | 19.55 Mn | 19.55 Mn | - | -250,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -917,552.00 |
| Dec 31, 2025 | -269,830.00 |
| Sep 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Mar 31, 2025 | -2.97 Mn |
| Dec 31, 2024 | -5.53 Mn |
| Sep 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | -94,925.00 |
| Mar 31, 2024 | -100,231.00 |
| Dec 31, 2023 | -38,982.00 |
| Sep 30, 2023 | -16,059.00 |
| Jun 30, 2023 | -49,222.00 |
| Mar 31, 2023 | -355,214.00 |